Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Tiffanie Villasana

Physician Assistant Houston, TX Physician Assistant

NPI 1922216407 CMS profile 10661097

9055 Katy Fwy Ste 306, Houston, TX 77024

Open in the dashboard

General payments

$10,710

599 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tiffanie Villasana of Houston, TX is reported in the CMS Open Payments database as having received $10,710 across 599 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,481 150
2024 General $2,101 91
2023 General $2,008 123
2022 General $2,196 119
2021 General $1,924 116

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tiffanie Villasana
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Tiffanie Villasana were reported at $2,481. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Tiffanie Villasana Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,924 $132 $37–$438 $132
2022 $2,196 $155 $48–$522 $149
2023 $2,008 $167 $52–$557 $160
2024 $2,101 $178 $55–$600 $164
2025 $2,481 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $1,182 69 payments
  2. AstraZeneca Pharmaceuticals LP $1,172 62 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $769 43 payments
  4. Dexcom, Inc. $587 27 payments
  5. Lilly USA, LLC $519 33 payments
  6. Sanofi-Aventis U.S. LLC $514 30 payments
  7. Amneal Pharmaceuticals LLC $513 30 payments
  8. Insulet Corporation $474 34 payments
  9. AbbVie, Inc. $464 25 payments
  10. Xeris Pharmaceuticals, Inc. $462 24 payments
  11. Other $4,055 222 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,668 598 payments
  2. Education $43 1 payment
Products named General payments · program years 2021–2025
  1. FARXIGA $1,107 58 payments
  2. Ozempic $785 45 payments
  3. Dexcom G6 Transmitter $523 23 payments
  4. UNITHROID $513 30 payments
  5. JARDIANCE $504 30 payments
  6. RYBELSUS $502 30 payments
  7. Omnipod $474 34 payments
  8. FreeStyle Libre $422 25 payments
  9. SYNTHROID $403 23 payments
  10. CeQur Simplicity $392 4 payments
  11. Other $6,077 359 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 73 drugs

Part D claims

5,357

Median for Physician Assistant: 241

Drug cost

$2,472,894

Median for Physician Assistant: $4,110

Branded share of claims

64.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 322 $490,308
Xultophy 100-3.6 Insulin Degludec/Liraglutide Brand 172 $274,143
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 255 $247,072
Mounjaro Tirzepatide Brand 186 $243,063
Jardiance Empagliflozin Brand 205 $208,863
Farxiga Dapagliflozin Propanediol Brand 230 $197,414
Prolia Denosumab Brand 59 $100,416
Trulicity Dulaglutide Brand 50 $68,623
Rybelsus Semaglutide Brand 42 $65,460
Tresiba Flextouch U-200 Insulin Degludec Brand 48 $54,055

The 10 drugs with the highest cost, of 73 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$71,296

Medicare's payments for the services billed

Medicare patients

206

Average age 73

Services billed

2,642

141 women, 65 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 68%
Chronic kidney disease 41%
Arthritis 39%
Ischemic heart disease 28%
Depression 20%
Heart failure 18%
Atrial fibrillation 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $138
  • Lilly USA, LLC $41
$179 205 —
TZIELD
  • SANOFI-AVENTIS U.S. LLC $141
$141 — —
UNITHROID
  • Amneal Pharmaceuticals LLC $127
$127 200 —
Ozempic
  • Novo Nordisk Inc $126
$126 322 —
SYNTHROID
  • AbbVie, Inc. $101
$101 221 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

599 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record